文献速递中医内科中药与中成药合理使用

厥阴颗粒治疗轻中度寻常型银屑病:多中心双盲随机安慰剂对照试验

Efficacy and safety of Jueyin granules for patients with mild-to-moderate psoriasis vulgaris: A multicenter, double-blind, randomized, placebo-controlled trial.
PubMed 文献 · J Ethnopharmacol · 2025-11-05

该多中心双盲随机安慰剂对照试验纳入195例体表面积评分<10的轻中度寻常型银屑病患者,按1:1随机分配接受厥阴颗粒或安慰剂治疗。第8周时厥阴颗粒组PASI和BSA评分下降显著优于安慰剂组,PASI50达标率51.09%对20.65%,且安全性良好,支持其作为银屑病的补充替代疗法。

要点

  • 厥阴颗粒可显著改善血热证轻中度银屑病患者的PASI和BSA评分。
  • 第8周PASI50达标率厥阴颗粒组51.09%,安慰剂组20.65%。
  • DLQI、VAS评分及复发率两组无统计学差异。

核心结论

  • 厥阴颗粒治疗轻中度寻常型银屑病安全有效,支持其作为补充替代疗法。

研究设计与样本

  • 患者按1:1比例经中央区组随机分配接受厥阴颗粒(n=99)或安慰剂(n=96)治疗。

主要发现

  • 第8周厥阴颗粒组PASI和BSA评分下降均显著大于安慰剂组(均P<0.001)。
  • 第16周厥阴颗粒组PASI和BSA评分改善仍维持(P<0.001和P=0.005)。
  • 第8周厥阴颗粒组PASI50达标率51.09%,安慰剂组20.65%(P<0.001)。
  • DLQI、VAS评分及复发率两组间无统计学差异。

临床怎么用

  • 对体表面积评分<10的轻中度寻常型银屑病血热证患者,可考虑口服厥阴颗粒作为补充替代治疗。
  • 疗效评估可关注第8周PASI50达标情况及PASI、BSA评分变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Psoriasis is an immune-mediated inflammatory skin disease. By more than a decade of clinical validation, Jueyin granules (JYG) have demonstrated multi-target synergistic immunomodulatory and anti-inflammatory effects, offering a characteristic Traditional Chinese Medicine (TCM) therapeutic approach for psoriasis. AIM OF THE STUDY: To assess the efficacy and safety of oral JYG in treating psoriasis with blood-heat syndrome. MATERIALS AND METHODS: Participants with body surface area (BSA) score less than 10 were allocated to receive JYG or placebo treatment in a 1:1 ratio through central area division and block randomization. The primary outcome is reduction of the psoriasis area severity index (PASI) score and proportion of participants achieving a greater than 50 % reduction in PASI scores (PASI50) at week 8. RESULTS: Between November 2019 and April 2022, 195 participants were randomly assigned to receive JYG (n = 99) or a placebo (n = 96) at five centers. The JYG group demonstrated significantly greater reductions in PASI and BSA scores than the placebo group at week 8 (both P < 0.001) and maintained these improvements at week 16 (P < 0.001 and P = 0.005, respectively). By week 8, 51.09 % of participants in the JYG group achieved PASI50, compared to 20.65 % in the placebo group (P < 0.001). However, there were no statistical differences in dermatology life quality index (DLQI), visual analog scale (VAS) scores, or relapse rate. CONCLUSIONS: This study provides conclusive evidence that JYG is a safe and effective treatment for patients with mild-to-moderate psoriasis. The current findings support its use as a complementary and alternative therapy for psoriasis.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Sun X, Wang Q, Ji Y, et al. Efficacy and safety of Jueyin granules for patients with mild-to-moderate psoriasis vulgaris: A multicenter, double-blind, randomized, placebo-controlled trial. J Ethnopharmacol. 2025. PMID: 41203092. doi:10.1016/j.jep.2025.120848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。